

David A Rizzieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2340161/publications.pdf>

Version: 2024-02-01

175
papers

4,441
citations

182225

30
h-index

129628

63
g-index

176
all docs

176
docs citations

176
times ranked

6829
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
3	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	3.2	70
4	P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. <i>Nature Cancer</i> , 2022, 3, 837-851.	5.7	9
5	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Journal of Clinical Oncology</i> , 2022, 40, 3032-3036.	0.8	19
6	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	1.3	15
7	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 181.e1-181.e9.	0.6	18
8	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	2.5	13
9	Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 262.e1-262.e11.	0.6	7
10	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
11	First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7502-7502.	0.8	16
12	Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).. <i>Journal of Clinical Oncology</i> , 2021, 39, e19043-e19043.	0.8	5
13	A phase 1 study of the pan- α -bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2943-2953.	2.0	42
14	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. <i>Blood Cancer Journal</i> , 2021, 11, 92.	2.8	2
15	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. <i>PLoS ONE</i> , 2021, 16, e0252995.	1.1	3
16	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
17	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 784.e1-784.e7.	0.6	4
18	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, , .	1.3	2
20	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Investigation, 2021, 39, 871-879.	0.6	6
21	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. Blood, 2021, 138, 1827-1827.	0.6	1
22	Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood, 2021, 138, 2318-2318.	0.6	0
23	A Study of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 4429-4429.	0.6	1
24	Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. Blood, 2021, 138, 874-874.	0.6	0
25	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood, 2021, 138, 3134-3134.	0.6	1
26	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	2.5	14
27	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, 1930-1936.	2.0	10
28	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS ONE, 2020, 15, e0238824.	1.1	4
29	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biology of Blood and Marrow Transplantation, 2020, 26, 2323-2328.	2.0	0
30	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research, 2020, 95, 106385.	0.4	26
31	Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects. American Journal of Hematology, 2020, 95, 662-671.	2.0	7
32	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH1/2</i> Mutations. Blood, 2020, 136, 5-7.	0.6	28
33	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood, 2020, 136, 130-136.	0.6	97
34	A phase I/II study of IMG632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.. Journal of Clinical Oncology, 2020, 38, TPS7563-TPS7563.	0.8	9
35	355...First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies. , 2020, , .		1
36	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2020, 136, 18-19.	0.6	0

#	ARTICLE	IF	CITATIONS
37	A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. <i>Blood</i> , 2020, 136, 5-5.	0.6	3
38	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. <i>New England Journal of Medicine</i> , 2019, 380, 1628-1637.	13.9	274
39	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2384-2393.	0.6	11
40	Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. <i>Cell Metabolism</i> , 2019, 29, 1217-1231.e7.	7.2	75
41	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
42	Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. <i>British Journal of Haematology</i> , 2019, 184, 647-650.	1.2	1
43	Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 7030-7030.	0.8	14
44	Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients. <i>Blood</i> , 2019, 134, 1319-1319.	0.6	0
45	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. <i>Blood</i> , 2019, 134, 5731-5731.	0.6	0
46	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
47	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	2.0	57
48	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. <i>Blood</i> , 2018, 131, 2661-2669.	0.6	313
49	Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. <i>Frontiers in Oncology</i> , 2018, 8, 669.	1.3	15
50	A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µCi/Kg/Dose. <i>Blood</i> , 2018, 132, 1457-1457.	0.6	11
51	Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2018, 132, 765-765.	0.6	9
52	ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3049-3049.	0.8	4
53	First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data. <i>Journal of Clinical Oncology</i> , 2018, 36, 7019-7019.	0.8	12
54	ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3102-TPS3102.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Molecular testing during AML treatment for early prediction of clinical response.. Journal of Clinical Oncology, 2018, 36, 7047-7047.	0.8	0
56	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	0.8	5
57	A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. British Journal of Haematology, 2017, 178, 434-441.	1.2	86
58	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncology, The, 2017, 18, 1317-1326.	5.1	148
59	A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.. Journal of Clinical Oncology, 2017, 35, 7010-7010.	0.8	1
60	Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.. Journal of Clinical Oncology, 2017, 35, 7035-7035.	0.8	14
61	Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (Bpd) in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 8008-8008.	0.8	1
62	A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.. Journal of Clinical Oncology, 2017, 35, TPS7070-TPS7070.	0.8	7
63	A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).. Journal of Clinical Oncology, 2017, 35, TPS7071-TPS7071.	0.8	0
64	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood, 2017, 130, 891-891.	0.6	6
65	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. Journal of Hematology and Oncology, 2016, 9, 71.	6.9	20
66	Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. Advances in Radiation Oncology, 2016, 1, 272-280.	0.6	10
67	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clinical Infectious Diseases, 2016, 63, 999-1006.	2.9	63
68	Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. European Journal of Haematology, 2016, 97, 313-320.	1.1	21
69	CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. Cancer Cell, 2016, 30, 792-805.	7.7	86
70	An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leukemia and Lymphoma, 2016, 57, 1800-1806.	0.6	57
71	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood, 2016, 128, 215-215.	0.6	25
72	Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.. Journal of Clinical Oncology, 2016, 34, 7006-7006.	0.8	11

#	ARTICLE	IF	CITATIONS
73	A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, TPS7071-TPS7071.	0.8	2
74	Shared decision-making tools for patients with hematologic malignancies.. Journal of Clinical Oncology, 2016, 34, e19007-e19007.	0.8	1
75	A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. American Journal of Hematology, 2015, 90, 796-799.	2.0	21
76	Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. Cell Stem Cell, 2015, 17, 152-164.	5.2	58
77	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncology, The, 2015, 16, 1099-1110.	5.1	249
78	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. Blood, 2015, 126, 2547-2547.	0.6	42
79	Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). Blood, 2015, 126, 458-458.	0.6	7
80	ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2015, 126, 4048-4048.	0.6	0
81	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma, 2014, 55, 2114-2119.	0.6	11
82	Is Timing Everything?. Biology of Blood and Marrow Transplantation, 2014, 20, 145-146.	2.0	0
83	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10A002. British Journal of Haematology, 2014, 165, 102-111.	1.2	78
84	Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. Nature Genetics, 2014, 46, 245-252.	9.4	97
85	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 257-263.	2.0	15
86	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 951-959.	2.0	37
87	Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 5658-5658.	0.6	2
88	First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).. Journal of Clinical Oncology, 2014, 32, 7030-7030.	0.8	4
89	Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update. Blood, 2014, 124, 1796-1796.	0.6	0
90	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. Blood, 2013, 122, 1548-1548.	0.6	1

#	ARTICLE	IF	CITATIONS
91	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.	0.6	23
92	Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7029-7029.	0.8	19
93	A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8535-8535.	0.8	4
94	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. <i>Blood</i> , 2012, 120, 3625-3625.	0.6	10
95	Results From the Dose Escalation Phase of a Randomized Phase 1â€”2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. <i>Blood</i> , 2012, 120, 414-414.	0.6	11
96	Pilot Study of Sorafenib for Myelodysplastic Syndrome. <i>Blood</i> , 2012, 120, 4948-4948.	0.6	1
97	A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosomeâ€”positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS6636-TPS6636.	0.8	0
98	Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigatorâ€™s choiceâ€”A subset analysis by prognostic group.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6525-6525.	0.8	0
99	Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS. <i>Blood</i> , 2012, 120, 4935-4935.	0.6	0
100	A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 3597-3597.	0.6	0
101	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. <i>Blood</i> , 2012, 120, 46-46.	0.6	1
102	Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1626-1626.	0.6	0
103	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. <i>Blood</i> , 2012, 120, 898-898.	0.6	0
104	Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 136-7.	0.3	0
105	Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors. <i>Cancer Investigation</i> , 2011, 29, 56-61.	0.6	4
106	Alemtuzumab for the prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011, 93, 586-593.	0.7	53
107	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2011, 118, 2012-2012.	0.6	1
108	High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 2681-2681.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 4127-4127.	0.6	9
110	Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience. Blood, 2011, 118, 5021-5021.	0.6	2
111	Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2011, 118, 767-767.	0.6	0
112	A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS) Tj ETQq0 0 0rgBT /Overlock 10 T	0.6	0
113	Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients. Blood, 2011, 118, 2619-2619.	0.6	0
114	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	0.6	0
115	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. Blood, 2011, 118, 1533-1533.	0.6	0
116	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5129-5129.	0.6	0
117	Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1107-1114.	2.0	79
118	Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.. Blood, 2010, 116, 2833-2833.	0.6	2
119	A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies. Blood, 2010, 116, 3294-3294.	0.6	4
120	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298.	0.6	3
121	Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt â€œ Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002. Blood, 2010, 116, 858-858.	0.6	17
122	Hematopoietic Stem Cell Transplantation Across Genetic Barriers Using a Nonmyeloablative Conditioning Regimen. , 2010, , 119-162.		0
123	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 803-803.	0.6	0
124	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	0.6	0
125	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	0.6	0
126	Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.. Blood, 2010, 116, 3466-3466.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. <i>Cancer</i> , 2009, 115, 2922-2929.	2.0	26
128	Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.. <i>Blood</i> , 2009, 114, 1047-1047.	0.6	4
129	Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.. <i>Blood</i> , 2009, 114, 1677-1677.	0.6	3
130	PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-Dependent Proliferation.. <i>Blood</i> , 2009, 114, 1697-1697.	0.6	1
131	Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy.. <i>Blood</i> , 2009, 114, 2076-2076.	0.6	4
132	Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009, 114, 2201-2201.	0.6	5
133	Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access) Tj ETQq1o1o.7843d4 rgBT	0.6	0
134	Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).. <i>Blood</i> , 2009, 114, 3295-3295.	0.6	5
135	Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway.. <i>Blood</i> , 2009, 114, 3730-3730.	0.6	2
136	Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.. <i>Blood</i> , 2009, 114, 3430-3430.	0.6	0
137	Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm.. <i>Blood</i> , 2009, 114, 2484-2484.	0.6	1
138	A Comprehensive Identification of the MicroRNA Transcriptome and Its Application in B Cell Malignancies.. <i>Blood</i> , 2009, 114, 2403-2403.	0.6	0
139	Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.. <i>Blood</i> , 2009, 114, 1029-1029.	0.6	6
140	Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	0
141	A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 2756-2762.	3.2	233
142	Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML. <i>Blood</i> , 2008, 112, 2968-2968.	0.6	1
143	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 342-342.	0.6	1
144	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. <i>Blood</i> , 2008, 112, 4403-4403.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	0.6	0
146	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. Blood, 2008, 112, 2180-2180.	0.6	0
147	Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution. Journal of Clinical Oncology, 2007, 25, 690-697.	0.8	188
148	Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.. Blood, 2007, 110, 3129-3129.	0.6	1
149	A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.. Blood, 2007, 110, 901-901.	0.6	0
150	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	0.6	1
151	Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3081-3081.	0.6	1
152	MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.. Blood, 2006, 108, 1967-1967.	0.6	8
153	A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.. Blood, 2006, 108, 1968-1968.	0.6	4
154	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	0.6	1
155	Antiproliferative Activity of ELACYT®, (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells.. Blood, 2006, 108, 1991-1991.	0.6	1
156	Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. Leukemia and Lymphoma, 2005, 46, 1455-1462.	0.6	8
157	A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.. Blood, 2005, 106, 2980-2980.	0.6	5
158	Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg®,) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.. Blood, 2005, 106, 4610-4610.	0.6	1
159	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.. Blood, 2005, 106, 5181-5181.	0.6	1
160	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	0.6	5
161	CLORETAZINE®, (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).. Blood, 2005, 106, 2786-2786.	0.6	0
162	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.. Blood, 2005, 106, 5501-5501.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.. Blood, 2005, 106, 4623-4623.	0.6	0
164	Efficacy of Performing a Second Non-Myeloablative Allogenic Stem Cell Transplant.. Blood, 2005, 106, 3664-3664.	0.6	0
165	Predictors of Survival in CLL: Multivariate Analyses Reveal Significant Correlation with IgVH Gene Mutation Status, Clinical Stage, and Cellular CD38 (but Not Zap-70) Expression.. Blood, 2005, 106, 5010-5010.	0.6	0
166	Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE, (VNP40101M).. Blood, 2005, 106, 2787-2787.	0.6	0
167	Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma. Cancer, 2004, 100, 1438-1448.	2.0	96
168	Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer, 2004, 100, 2408-2414.	2.0	18
169	Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood, 2004, 104, 642-648.	0.6	53
170	Campath-1H May Have Activity in the Treatment of Multiple Myeloma.. Blood, 2004, 104, 4931-4931.	0.6	1
171	Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clinical Cancer Research, 2003, 9, 663-8.	3.2	17
172	Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2002, 20, 674-679.	0.8	36
173	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood, 2001, 97, 2177-2179.	0.6	51
174	Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood, 2001, 98, 3486-3488.	0.6	53
175	Nuclear factor- κ B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 2001, 98, 2301-2307.	0.6	695